Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions.
暂无分享,去创建一个
G J Barker | G. Barker | D. Miller | C. Davie | W. Mcdonald | P. Tofts | C. Hawkins | P S Tofts | W I McDonald | D H Miller | C A Davie | C P Hawkins | A. Brennan | A Brennan | D. Miller | D. Miller | D. Miller
[1] R. Kamman,et al. In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis. , 1992, Archives of neurology.
[2] J. Frahm,et al. Improvements in localized proton NMR spectroscopy of human brain. Water suppression, short echo times, and 1 ml resolution , 1990 .
[3] William H. Oldendorf,et al. N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.
[4] J. Frahm,et al. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites , 1989, Magnetic resonance in medicine.
[5] P E Wright,et al. Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. , 1986, The Journal of biological chemistry.
[6] P M Matthews,et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.
[7] F. Roncaroli,et al. Neuropathology of multiple sclerosis , 2012 .
[8] P A Narayana,et al. Proton MR spectroscopy of gadolinium‐enhanced multiple sclerosis plaques , 1992, Journal of magnetic resonance imaging : JMRI.
[9] J. Frahm,et al. Acute demyelinating disease. Classification and non‐invasive diagnosis , 1992, Acta neurologica Scandinavica.
[10] J. Cumings,et al. Biochemistry and the Central Nervous System , 1967, Neurology.
[11] T Revesz,et al. Multiple sclerosis. Pathology of recurrent lesions. , 1993, Brain : a journal of neurology.
[12] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[13] T. Patel,et al. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. , 1979, The Biochemical journal.
[14] P Rudge,et al. The site of the lesion causing deafness in multiple sclerosis. , 1988, Scandinavian audiology.
[15] K. Brindle,et al. The appearance of neutral lipid signals in the 1H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmic lipid droplets , 1993, Magnetic resonance in medicine.
[16] D. Gadian,et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[17] D. Gadian,et al. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis , 1991, The Lancet.
[18] H. Bruhn,et al. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo , 1992, Annals of neurology.
[19] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[20] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[21] G J Barker,et al. The proton NMR spectrum in acute EAE: The significance of the change in the Cho:Cr ratio , 1993, Magnetic resonance in medicine.
[22] Henry McIlwain. Biochemistry and the Central Nervous System , 1955 .
[23] Detection of thymosin beta 4 in situ in a guinea pig cerebral cortex preparation using 1H NMR spectroscopy. , 1992, The Journal of biological chemistry.
[24] J. Olesen,et al. In vivo determination of T1 and T2 in the brain of patients with severe but stable multiple sclerosis , 1988, Magnetic resonance in medicine.
[25] J. Taubenberger,et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.
[26] B E Kendall,et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.
[27] A. Thompson,et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[28] W. Stehbens. Pathology of the cerebral blood vessels , 1972 .
[29] W. Mcdonald,et al. The pathological evolution of multiple sclerosis , 1992, Neuropathology and applied neurobiology.
[30] D. N. Landon,et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. , 1990, Brain : a journal of neurology.
[31] P. Jenner. Biochemistry and the Central Nervous System (5th Ed.) , 1986 .
[32] K. Behar,et al. Assignment of resonances in the 1H spectrum of rat brain by two‐dimensional shift correlated and j‐resolved NMR spectroscopy , 1991, Magnetic resonance in medicine.
[33] D. Paty,et al. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products , 1993, The Lancet.
[34] J. Dawson,et al. The Histology of Disseminated Sclerosis , 1916, Edinburgh Medical Journal.
[35] R. Poston,et al. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis , 1989, Journal of the Neurological Sciences.
[36] R E Lenkinski,et al. MR proton spectroscopy in multiple sclerosis. , 1992, AJNR. American journal of neuroradiology.
[37] H. Powell,et al. Pathology of multiple sclerosis. , 1983, Neurologic clinics.
[38] P M Matthews,et al. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.
[39] G. Barker,et al. Detection of myelin breakdown products by proton magnetic resonance spectroscopy , 1993, The Lancet.
[40] J. Olesen,et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis , 1991, Magnetic resonance in medicine.